Researchers at the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine’s Abramson Cancer Center announced on Mar. 12 that they have developed a new approach to eliminate precancerous cells in the pancreas before they develop into tumors. The findings, published in Science, show that using experimental therapies to target microscopic lesions nearly doubled survival rates in mouse models of pancreatic ductal adenocarcinoma compared to treatment after cancer had already formed.
The study is significant because pancreatic cancer has limited treatment options and no proven screening or prevention strategies. The research provides evidence for the emerging field of cancer interception, which aims to stop cancer development at its earliest stages. "I’m convinced that cancer interception will become the next frontier of cancer therapy," said Robert Vonderheide, MD, DPhil, director of the Abramson Cancer Center. "Pancreatic cancer has a stubbornly poor prognosis, limited treatment options and no proven screening or prevention strategies. If we can find a way to intercept it—to identify and neutralize abnormalities on their earliest steps toward malignancy—it would be a game-changer."
Unlike traditional prevention methods such as vaccines or lifestyle changes, cancer interception targets early cellular changes before malignancy occurs. Lead author Minh Than, MD, PhD said, "This study provides a preclinical proof-of-concept that medical cancer interception works better than treatment after a diagnosis. This study shows us the power of being proactive, rather than reactive, when it comes to cancer. It will be exciting to evaluate this in our patients in the next phase of this work."
The team used two experimental inhibitors targeting KRAS mutations—common drivers in over 90 percent of pancreatic cancers—in immunocompetent mouse models considered gold standard for such research. Treatment with these compounds reduced precancerous lesions and increased survival times significantly compared to untreated groups.
Ben Stanger, MD, PhD said, "The direct comparison in this study puts PanINs on the map as potential targets for cancer interception and opens the door for exploring KRAS inhibitors in a new setting." He noted challenges remain since PanINs are not visible through imaging exams and applying these findings clinically will require careful selection of high-risk patient populations.
Looking ahead, researchers plan clinical trials focusing on individuals with genetic predispositions or those already monitored for pancreatic cysts. The approach could eventually expand to people at intermediate risk if further studies support its effectiveness.
